🇺🇸 sigvotatug vedotin in United States
13 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 13
Most-reported reactions
- Toxicity To Various Agents — 3 reports (23.08%)
- Decreased Appetite — 2 reports (15.38%)
- Atrial Thrombosis — 1 report (7.69%)
- Blood Creatinine Increased — 1 report (7.69%)
- Cardiac Tamponade — 1 report (7.69%)
- Condition Aggravated — 1 report (7.69%)
- Haemoglobin Decreased — 1 report (7.69%)
- Heavy Menstrual Bleeding — 1 report (7.69%)
- Pericardial Effusion — 1 report (7.69%)
- Pulmonary Embolism — 1 report (7.69%)
sigvotatug vedotin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is sigvotatug vedotin approved in United States?
sigvotatug vedotin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for sigvotatug vedotin in United States?
Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.